Citations

Clear

6273 citation(s) found for "To, Andrew".

Effect of Left Cardiac Sympathetic Denervation on the Electromechanical Window in Patients with either Type 1 or Type 2 Long QT Syndrome: A Pilot Study
Schneider, Andrew E. , Bos, J. Martijn , Ackerman, Michael J. , Bos, Johan M

Mayo Clinic

Congenital Heart Disease | February 18, 2016 | Volume: 11 | Issue: 5 | Pages: 437-443

10.1111/chd.12332 | PMID 26887900 Get It

National Randomized Controlled Trial of Virtual House Calls for People with Parkinson's Disease: Interest and Barriers
Dorsey, E. Ray , Achey, Meredith A. , Beck, Christopher A. , Beran, Denise B., Biglan, Kevin , Boyd, Cynthia M. , Schmidt, Péter , Simone, Richard, Willis, Allison W. , Galifianakis, Nicholas B. , Katz, Maya , Dodenhoff, Kristen A. , Ziman, Nathan, Aldred, Jason , Carter, Julie, Jimenez‐Shahed, Joohi , Hunter, Christine , Spindler, Meredith , Morgan, John C. , McLane, Dedi, Hickey, Patrick , Gauger, Lisa, Richard, Irene Hegeman, Bull, Michael, Mejia, Nicte I. , Bwala, Grace, Nance, Martha , Shih, Ludy C. , Anderson, Lauren , Singer, Carlos , Zadikoff, Cindy , Okon, Natalia, Feigin, Andrew, Ayan, J., Vaughan, Christina , Cooper, Jessica , Webb, S. J., Dhall, Rohit , Hassan, Anhar , Weis, Delana, DeMello, Steven, Smith, Joseph M. , Keenan, H. Tait, Korn, Ryan, Schwarz, Heidi B., Stevenson, E. Anna , Zhu, William , Tanner, Caroline M. , Mari, Zoltan K. , Pahwa, Rajesh , Riggare, Sara S. , Wicks, Paul J , Sharma, Saloni , Jimenez-Shahed, Joohi

Mayo Clinic

Telemedicine and e-Health | February 17, 2016 | Volume: 22 | Issue: 7 | Pages: 590-598

10.1089/tmj.2015.0191 | PMID 26886406 Get It

Background: Delivering specialty care remotely directly into people's homes can enhance access for and improve the healthcare of individuals with chronic conditions. However, evidence supporting this approach is limited. Materials and Methods: Connect.Parkinson is a randomized comparative effectiveness study that compares usual care of individuals with Parkinson's disease in the community with usual care augmented by virtual house calls with a Parkinson's disease specialist from 1 of 18 centers nationally. Individuals in the intervention arm receive four virtual visits from a Parkinson's disease specialist over 1 year via secure, Web-based videoconferencing directly into their homes. All study activities, including recruitment, enrollment, and assessments, are conducted remotely. Here we report on interest, feasibility, and barriers to enrollment in this ongoing study. Results: During recruitment, 11,734 individuals visited the study's Web site, and 927 unique individuals submitted electronic interest forms. Two hundred ten individuals from 18 states enrolled in the study from March 2014 to June 2015, and 195 were randomized. Most participants were white (96%) and college educated (73%). Of the randomized participants, 73% had seen a Parkinson's disease specialist within the previous year. Conclusions: Among individuals with Parkinson's disease, national interest in receiving remote specialty care directly into the home is high. Remote enrollment in this care model is feasible but is likely affected by differential access to the Internet.
Carbapenem- and Colistin-Resistant Enterobacter cloacae from Delta, Colorado, in 2015
Norgan, Andrew P. , Freese, Jarred M., Tuin, Patricia M., Cunningham, Scott A. , Jeraldo, Patricio , Patel, Robin , Jeraldo, Patricio R , Patel, Robin , Norgan, Andrew P , Cunningham, Scott A

Mayo Clinic

Antimicrobial Agents and Chemotherapy | February 17, 2016 | Volume: 60 | Issue: 5 | Pages: 3141-3144

10.1128/aac.03055-15 | PMID 26883705 Get It

ABSTRACT Resistance to carbapenems in Enterobacteriaceae is a clinical problem of growing significance. Difficulty in treating multidrug-resistant Gram-negative organisms with conventional antibiotics has led to a renewed and increasing use of polymyxin compounds, such as colistin. Here, we report the isolation of carbapenem- and colistin-resistant Enterobacter cloacae from a polymicrobial lower extremity wound in an ambulatory patient. Whole-genome sequencing demonstrated the presence of chromosomal bla IMI-1 and bla AmpC , as well as numerous efflux pump genes.
Nodular Fasciitis of the Orbit: A Case Report Confirmed by Molecular Cytogenetic Analysis
Anzeljc, Andrew J., Oliveira, André M. , Kim, Hee Joon , Hayek, Brent , Grossniklaus, Hans E.

Mayo Clinic

Ophthalmic Plastic & Reconstructive Surgery | February 14, 2016 | Volume: 33 | Issue: 3S | Pages: S152-S155

10.1097/iop.0000000000000649 | PMID 26882059 Get It

Nodular fasciitis is a benign fibroblastic proliferation typically found in the subcutaneous tissue or superficial fascia of the extremities that is often confused for malignancy. These lesions rarely occur on the eyelids and ocular adnexa and are seldom analyzed by ophthalmic pathologists. USP6 gene rearrangement has been recently demonstrated in nodular fasciitis and this rearrangement may lead to the formation of a fusion gene MYH9-USP6 in some cases. Herein, the authors describe a 38-year-old woman with a 6-month history of a progressively enlarging mass beneath her right medial upper eyelid. Histopathologic analysis of the excisional biopsy confirmed classic features of nodular fasciitis. Molecular cytogenetic analysis revealed a rearrangement of the USP6 locus, confirming the diagnosis of benign nodular fasciitis.
Primary Pseudomyogenic Hemangioendothelioma of Bone
Inyang, Alero F., Mertens, Fredrik , Puls, Florian , Vaiyapuri, Sumathi , Inwards, Carrie Y., Folpe, Andrew L. , Zhang, Yaxia , Symmans, Pennie, Nielsen, G. Petur , Nguyễn, Văn Hùng , Rosenberg, Andrew E. , Inyang, Alero, Lee, Cheng‐Han , Rubin, Brian P.

Mayo Clinic

American Journal of Surgical Pathology | February 12, 2016 | Volume: 40 | Issue: 5 | Pages: 587-598

10.1097/pas.0000000000000613 | PMID 26872012 Get It

Pseudomyogenic hemangioendothelioma (PMH) is a well-recognized neoplasm that usually arises in the soft tissue; concurrent bone involvement occurs in 24% of cases. PMH of bone without soft tissue involvement is rare. We describe the clinicopathologic findings of 10 such cases, the largest series reported to date. The study included 9 male and 1 female patient; their ages ranged from 12 to 74 years (mean 36.7 y). All patients had multiple tumors with a distinct regional distribution: 45% restricted to the lower extremity; 25% to the spine and pelvis; and 15% to the upper extremity. On imaging studies the tumors were well circumscribed and lytic. The neoplasms were composed of spindled cells arranged in intersecting fascicles with scattered epithelioid cells; epithelioid cells predominated in 3 cases. The neoplastic cells contained abundant densely eosinophilic cytoplasm and vesicular nuclei. There was limited cytologic atypia and necrosis, few mitoses (0 to 2/10 high-power fields), and inconspicuous stroma. Unique findings included abundant intratumoral reactive woven bone and hemorrhage with numerous osteoclast-like giant cells. Immunohistochemically, most tumors were positive for keratin, ERG, and CD31; CD34 was negative. The balanced t(7:19)(q22;13) translocation was documented in 3 cases. Follow-up is limited, but no patient developed documented visceral dissemination, and all have stable or progressive osseous disease. PMH exclusively involving bone is rare. It is multicentric, often involves the lower extremity, and has unusual morphology. The differential diagnosis includes epithelioid vascular neoplasms, giant cell tumor, bone forming neoplasms, and metastatic carcinoma. Because of its rarity, unusual presentation, and morphology, accurate diagnosis can be challenging.
Novel Percutaneous Epicardial Autonomic Modulation in the Canine for Atrial Fibrillation: Results of an Efficacy and Safety Study
Madhavan, Malini , Venkatachalam, K, Swale, M., Gard, Joseph J., Johnson, Susan B., Suddendorf, Scott H., Mikell, Susan B. , Ladewig, Dorothy J., NOSBUSH, TONI GRABINGER, Danielsen, Andrew J., Knudson, Mark B., Asirvatham, Samuel J. , Knudson, Mark, DeSimone, Christopher V. , Asirvatham, Samuel J

Mayo Clinic

Pacing and Clinical Electrophysiology | February 8, 2016 | Volume: 39 | Issue: 5 | Pages: 407-417

10.1111/pace.12824 | PMID 26854009 Get It

BackgroundEndocardial ablation of atrial ganglionated plexi (GP) has been described for treatment of atrial fibrillation (AF). Our objective in this study was to develop percutaneous epicardial GP ablation in a canine model using novel energy sources and catheters.MethodsPhase 1: The efficacy of several modalities to ablate the GP was tested in an open chest canine model (n = 10). Phase 2: Percutaneous epicardial ablation of GP was done in six dogs using the most efficacious modality identified in phase 1 using two novel catheters.ResultsPhase 1: Direct current (DC) in varying doses (blocking [7–12 μA], electroporation [300–500 μA], ablation [3,000–7,500 μA]), radiofrequency ablation (25–50 W), ultrasound (1.5 MHz), and alcohol (2–5 mL) injection were successful at 0/8, 4/12, 5/7, 3/8, 1/5, and 5/7 GP sites. DC (500–5,000 μA) along with alcohol irrigation was tested in phase 2. Phase 2: Percutaneous epicardial ablation of the right atrium, oblique sinus, vein of Marshall, and transverse sinus GP was successful in 5/6 dogs. One dog died of ventricular fibrillation during DC ablation at 5,000 μA. Programmed stimulation induced AF in six dogs, preablation and no atrial arrhythmia in three, flutter in one, and AF in one postablation. Heart rate, blood pressure, effective atrial refractory period, and local atrial electrogram amplitude did not change significantly postablation. Microscopic examination showed elimination of GP, and minimal injury to atrial myocardium.ConclusionPercutaneous epicardial ablation of GP using DC and novel catheters is safe and feasible and may be used as an adjunct to pulmonary vein isolation in the treatment of AF in order to minimize additional atrial myocardial ablation.
The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience
Dyke, Daniel L. Van , Werner, Lillian , Rassenti, Laura Z., Ghia, Emanuella, Heerema, Nyla A. , Cin, Paola Dal , Aquila, Marie Dell, Sreekantaiah, Chandrika, Greaves, Andrew, Van Dyke, Daniel L, Neuberg, Donna , Kipps, Thomas J. , Kay, Neil E.

Mayo Clinic

British Journal of Haematology | February 5, 2016 | Volume: 173 | Issue: 1 | Pages: 105-113

10.1111/bjh.13933 | PMID 26848054 Get It

SummaryThis study revisited the Dohner prognostic hierarchy in a cohort of 1585 well‐documented patients with chronic lymphocytic leukaemia. The duration of both time to first treatment (TTFT) and overall survival (OS) were significantly longer than observed previously, and this is at least partly due to improved therapeutic options. Deletion 13q remains the most favourable prognostic group with median TTFT and OS from fluorescence in situ hybridization (FISH) testing of 72 months and >12 years, respectively. Deletion 11q had the poorest median TTFT (22 months) and 17p deletion the poorest median OS (5 years). The percentages of abnormal nuclei were significantly associated with differential TTFT for the trisomy 12, 13q and 17p deletion cohorts but not for the 11q deletion cohort. From the date of the first FISH study, patients with >85% 13q deletion nuclei had a notably shorter TTFT (24 months). Patients with ≤20% 17p deletion nuclei had longer median TTFT and OS from the date of the first FISH study (44 months and 11 years), and were more likely to be IGHV mutated.
Clinical delineation of the PACS1‐related syndrome—Report on 19 patients
Schuurs-Hoeijmakers, Janneke , Landsverk, Megan , Foulds, Nicola , Kukolich, Mary K. , Gavrilova, Ralitza H. , Greville‐Heygate, Stephanie , Hanson‐Kahn, Andrea , Bernstein, Jonathan A. , Glass, Jennifer, Burrow, Thomas Andrew, Husami, Ammar , Collins, Kathleen , Wusik, Katie, Aa, Nathalie Van der, Kooy, R. Frank , Brown, Kate Tatton, Gadzicki, Dorothea, Kini, Usha , McGehee, Frank T., Selby, Katherine, Tarailo‐Graovac, Maja , Allen, Margot Van, Stavropoulos, Dimitri J. , Marshall, Christian R. , Merico, Daniele , Gregor, Anne , Zweier, Christiane , Chu, Yoyo W. Y., Vries, Bert B.A. de , Brunner, Han G. , study, DDD, Chitayat, David A. , Collins, Kathleen , Álvarez, Sara , Fernández‐Jaén, Alberto , Allen, Margot I. Van, Karnebeek, Clara van , Hopkin, Robert J. , Chung, Hon-Yin B , Devriendt, Koenraad , Hurles, Matthew E. , study, DDD, Kooy, Frank , de Vries, Bert B A , Marshall, Christian R.

Mayo Clinic

American Journal of Medical Genetics Part A | February 4, 2016 | Volume: 170 | Issue: 3 | Pages: 670-675

10.1002/ajmg.a.37476 | PMID 26842493 Get It

We report on 19 individuals with a recurrent de novo c.607C>T mutation in PACS1. This specific mutation gives rise to a recognizable intellectual disability syndrome. There is a distinctive facial appearance (19/19), characterized by full and arched eyebrows, hypertelorism with downslanting palpebral fissures, long eye lashes, ptosis, low set and simple ears, bulbous nasal tip, wide mouth with downturned corners and a thin upper lip with an unusual “wavy” profile, flat philtrum, and diastema of the teeth. Intellectual disability, ranging from mild to moderate, was present in all. Hypotonia is common in infancy (8/19). Seizures are frequent (12/19) and respond well to anticonvulsive medication. Structural malformations are common, including heart (10/19), brain (12/16), eye (10/19), kidney (3/19), and cryptorchidism (6/12 males). Feeding dysfunction is presenting in infancy with failure to thrive (5/19), gastroesophageal reflux (6/19), and gastrostomy tube placement (4/19). There is persistence of oral motor dysfunction. We provide suggestions for clinical work‐up and management and hope that the present study will facilitate clinical recognition of further cases. © 2016 Wiley Periodicals, Inc.
Prime, Shock, and Kill: Priming CD4 T Cells from HIV Patients with a BCL-2 Antagonist before HIV Reactivation Reduces HIV Reservoir Size
Sainski, Amy M., Dai, Haiming , Natesampillai, Sekar, Pang, Yuan‐Ping , Bren, Gary D., Correia, Maria Cristina Miranda de Araujo, Sampath, Rahul , Rizza, Stacey A. , O’Brien, Daniel R. , Yao, Joseph D. , Badley, Andrew D. , Correia, Cristina , Cummins, Nathan W. , de Araujo Correia, Maria Cristina Miranda, Kaufmann, Scott H. , Correia, Maria Cristina Miranda de Araujo, Correia, Cristina , Badley, Andrew D , Pang, Yuan-Ping , Dai, Haiming

Mayo Clinic

Journal of Virology | February 4, 2016 | Volume: 90 | Issue: 8 | Pages: 4032-4048

10.1128/jvi.03179-15 | PMID 26842479 Get It

ABSTRACT Understanding how some HIV-infected cells resist the cytotoxicity of HIV replication is crucial to enabling HIV cure efforts. HIV killing of CD4 T cells that replicate HIV can involve HIV protease-mediated cleavage of procaspase 8 to generate a fragment (Casp8p41) that directly binds and activates the mitochondrial proapoptotic protein BAK. Here, we demonstrate that Casp8p41 also binds with nanomolar affinity to the antiapoptotic protein Bcl-2, which sequesters Casp8p41 and prevents apoptosis. Further, we show that central memory CD4 T cells (T CM ) from HIV-infected individuals have heightened expression of BCL-2 relative to procaspase 8, possibly explaining the persistence of HIV-infected T CM despite generation of Casp8p41. Consistent with this hypothesis, the selective BCL-2 antagonist venetoclax induced minimal killing of uninfected CD4 T cells but markedly increased the death of CD4 T cells and diminished cell-associated HIV DNA when CD4 T cells from antiretroviral therapy (ART)-suppressed HIV patients were induced with αCD3/αCD28 to reactivate HIV ex vivo . Thus, priming CD4 T cells from ART suppressed HIV patients with a BCL-2 antagonist, followed by HIV reactivation, achieves reductions in cell-associated HIV DNA, whereas HIV reactivation alone does not. IMPORTANCE HIV infection is incurable due to a long-lived reservoir of HIV + memory CD4 T cells, and no clinically relevant interventions have been identified that reduce the number of these HIV DNA-containing cells. Since postintegration HIV replication can result in HIV protease generation of Casp8p41, which activates BAK, causing infected CD4 T cell death, we sought to determine whether this occurs in memory CD4 T cells. Here, we demonstrate that memory CD4 T cells can generate Casp8p41 and yet are intrinsically resistant to death induced by diverse stimuli, including Casp8p41. Furthermore, BCL-2 expression is relatively increased in these cells and directly binds and inhibits Casp8p41's proapoptotic effects. Antagonizing BCL-2 with venetoclax derepresses this antagonism, resulting in death, preferentially in HIV DNA containing cells, since only these cells generate Casp8p41. Thus, BCL-2 antagonism is a clinically relevant intervention with the potential to reduce HIV reservoir size in patients.
A targeted genetic association study of epithelial ovarian cancer susceptibility
Earp, Madalene A. , Winham, Stacey J. , Sicotte, Hugues , Chien, Jeremy , Goodman, Marc T. , Levine, Douglas A. , Monteiro, Álvaro N.A. , Ness, Roberta B., Pearce, Celeste Leigh, Rossing, Mary Anne, Tworoger, Shelley S. , Wentzensen, Nicolas , Bisogna, Maria, Brinton, Louise A. , Brooks‐Wilson, Angela , Carney, Michael E. , Cunningham, Julie M. , Edwards, Robert P., Fogarty, Zachary C. , Iversen, Edwin S., Kraft, Peter , Le, Nhu D. , Lin, Hui‐Yi , Lissowska, Jolanta , Moysich, Kirsten B. , Olson, Sara H. , Pike, Malcolm C. , Rider, David N., Terry, Kathryn L. , Thompson, Pamela J., Vierkant, Robert A. , Vitonis, Allison F., Wu, Anna H. , Phelan, Catherine M., Schildkraut, Joellen M. , Chen, Y. Ann , Sellers, Thomas A. , Goode, Ellen L. , Earp, Madalene, Larson, Nicholas, Larson, Nicholas B. , Permuth, Jennifer B. , Anton‐Culver, Hoda , Bandera, Elisa V. , Berchuck, Andrew , Cook, Linda S. , Cramer, Daniel W. , Doherty, Jennifer A. , Larson, Melissa C. , Modugno, Francesmary , Poole, Elizabeth M. , Berg, David Van Den , Wilkens, Lynne R. , Yang, Hannah , Ziogas, Argyrios , Fridley, Brooke L. , Winham, Stacey J , Tworoger, Shelley S , Vierkant, Robert A , Chien, Jeremey , Monteiro, Alvaro N , Moysich, Kirsten , Lissowska, Jolanta , Brooks-Wilson, Angela R , Lin, Hui-Yi , Fogarty, Zachary C , Kraft, Peter , Goodman, Marc T

Mayo Clinic

Oncotarget | February 2, 2016 | Volume: 7 | Issue: 7 | Pages: 7381-7389

10.18632/oncotarget.7121 | PMID 26848776 Get It